10.1016/j.expneurol.2015.11.006 (2016)
Clinical trials demonstrate remarkable efficacy in treating withdrawal symptoms, with 97% of opiate-dependent and 87% of alcohol-dependent patients experiencing symptom relief
It's especially useful for patients with chronic fatigue, Long COVID, suspected poor mitochondrial function, and those recovering from substance addiction
The aforementioned considerations imply that Nrf2 may be considered a target in some situations, thus supporting a possible use of specific inhibitors, or rather a defensive weapon to activate, thus stimulating the interest towards its activators
doi:10.1309/cvhkle2r4w68k2nq
Peer review Peer review information Nature Catalysis thanks Steffen N Lindner, Diethard Mattanovich and the other, anonymous, reviewer(s) for their contribution to the peer review of this work